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Background: CD4+ cell counts reflect immunologic status of human immunodeficiency virus (HIV) patients. Recommended 
CD4+ cell counts for the initiation of highly active antiretroviral therapy (HAART) has increased over the past several years in var-
ious HIV treatment guidelines. We investigated the trend of CD4+ cell counts at diagnosis and treatment start using data from the 
Korea HIV/acquired immune deficiency syndrome (AIDS) Cohort Study.
Materials and Methods: The Korea HIV/AIDS Cohort Study started in 2006 and enrolled HIV patients from 21 tertiary and secondary 
hospitals in South Korea. The data for CD4+ cell counts at diagnosis and HAART initiation from these HIV patients were analyzed 
by three-year time intervals and presented by number of CD4+ cells (≤100, 101-200, 201-350, 351-500 and >500 cells/mm3). The 
HIV-RNA titer at diagnosis and HAART initiation were presented by 3-year intervals by groups ≤50,000, 50,001-100,000, 100,001-
200,000, 200,001-1,000,000, and >1,000,000 copies/mL.
Results: Median values of CD4+ cell count and HIV-RNA titer at initial HIV diagnosis were 247 cells/mm3 and 394,955 copies/mL, 
respectively. At time of initiating HAART, median values of CD4+ cell count and HIV-RNA were 181 cells/mm3 and 83,500 cop-
ies/mL, respectively. Patients with low CD4+ cell count (CD4+ cell count ≤200 cells/mm3) at diagnosis (31-51%) and initiation of 
HAART accounted for the largest proportion (30-65%) over the three-year time intervals. This proportion increased until 2010-2012.
Conclusion: CD4+ cell count at initiation of HAART was found to be very low, and the increase in late initiation of HAART in 
recent years is of concern. We think that this increase is primarily due to an increasing proportion of late presenters. We recom-
mend early detection of HIV patients and earlier start of HAART in order to treat and prevent spread of HIV infection. 
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Introduction
Due to developments of highly active antiretroviral therapy 
(HARRT), morbidity and mortality related to human immu-
nodeficiency virus (HIV) infected patients has reduced mark-
edly [1, 2]. In 2014, the number of HIV-infected patients glob-
ally was about 36.9 million (34.3 - 41.4 million), and 2 million 
people were newly diagnosed with HIV [3]. At this time, 15 
million HIV patients were receiving HAART [3]. Previous stud-
ies have found that starting HAART when the CD4+ cell count 
is high is recommended for improved virologic and immuno-
logic recovery and prevents disease progression [4-6]. Starting 
HAART when CD4+ cell counts are already low results in ac-
quired immunodeficiency syndrome (AIDS) defining disease 
for many patients [7]; HIV-infected patients who started 
HAART with a CD4+ cell count <200 cells/mm3 may not reach 
a normal CD4+ cell count [6]. In addition, early treatment of 
HAART prevents sexual transmission among serodiscordant 
couples [8]. Considering these clinical findings, many HIV/
AIDS expert groups have updated their clinical guidelines re-
garding the recommended time point for initiating HAART. 
The European AIDS Clinical Society (EACS) recommends that 
patients whose CD4+ cell counts are <350 cells/mm3 initiate 
HAART [9]. However, the Department of Health and Human 
Services (DHHS) guidelines strongly recommend that 
HIV-positive patients with CD4+ cell count ≤500 cells/mm3 
should initiate HAART [10]. The World Health Organization 
(WHO) also recently updated their treatment guidelines to 
advise that HAART should be initiated for all HIV-positive 
adult patients, regardless of WHO clinical stage and CD4+ cell 
count [11]. Consistent with these other recommendations, the 
Korean Society for AIDS revised their guidelines in 2013 to 
recommend that all HIV-infected patients, regardless of CD4+ 
cell count, initiate HAART. The guidelines also favor treatment 
of HIV-positive patients whose infection status is acute or who 
were recently infected [12]. Although previous clinical data 
and guidelines recommend early initiation of ART, most 
HIV-infected patients initiate HAART when they are diag-
nosed with low CD4+ cell counts [2, 13, 14]. In Korea, the total 
number of patients infected with HIV in 2015 was 10,502 and 
there were 1,052 newly infected patients; incidence has been 
observed to be increasing steadily. In addition, with the sup-
port of the national HIV/AIDS policy, the proportion of pa-
tients treated with HAART has increased. It is necessary to 
know the real status of CD4+ cell count and HIV-RNA at the 
HIV diagnosis and HAART initiation. Therefore, we re-
searched CD4+ cell count and HIV-RNA of Korean HIV- in-
fected patients at the time points of diagnosis and initiation of 
treatment, using Korea HIV/AIDS Cohort Study data. 
Materials and Methods 
The Korea HIV/AIDS Cohort Study was a prospective obser-
vational cohort study with patients from 21 tertiary or second-
ary hospitals in South Korea, initiated in 2006. The Korea HIV/
AIDS Cohort Study collected data on HIV-infected individuals, 
including socioeconomic status, route of infection, HAART, 
conventional laboratory data, immunological and viral labo-
ratory data, and information on opportunistic infections. The 
institutional review board approval was obtained from all 
participating hospitals.
Within the cohort study population, patients who had CD4+ 
cell count and HIV-RNA titer data at the time of diagnosis and 
HAART initiation were included in this study. Data were strat-
ified on the basis of CD4+ cell count (≤100, 101-200, 201-350, 
351-500, and >500 cells/mm3) and HIV-RNA titer (≤50,000, 
50,001-100,000, 100,001-200,000, 200,001-1,000,000, and 
>1,000,000 copies/mL), and analyzed by 3-year time intervals. 
The stratified data are presented with percentages, average 
values, mean values, and quartile values. 
Additionally, we investigated age, sex, transmission route, 
and the past medical history of patients with a CD4+ cell 
count at the time of diagnosis. We compared these factors 
based on the CD4+ cell count at diagnosis (cutoff point: CD4+ 
cell count 200 cells/mm3 or 350 cells/mm3). The Student-t test 
or the Wilcoxon Rank-Sum test was used to analyze continu-
ous variables, and the chi-square test or the Fisher exact test 
was used for categorical variables. Statistical analyses were 
performed using R statistics version 3.2.1 (R Foundation for 
Statistical Computing, Vienna, Austria), and P <0.05 was con-
sidered statistically significant.
Result
1. Trend of CD4+ cell count and HIV-RNA titer at the time 
of diagnosis
As of August 2015, 1,356 HIV-infected patients were enrolled 
in the Korea HIV/AIDS Cohort Study. Among the Cohort 
Study population, 1,124 HIV-infected patients were suitable 
for analysis of CD4+ cell count at time of diagnosis. Mean and 
median values of CD4+ cell counts were 271 cells/mm3 and 
247 cells/mm3 (interquartile range [IQR] 104 - 390 cells/mm3), 
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respectively. Table 1 shows mean and median values of CD4+ 
cell count at HIV diagnosis, according to three-year intervals. 
The patients suitable for analysis comprised between 1% and 
15% of new patients with HIV/AIDS in each period (Table 1). 
The median age at diagnosis was 40 years (overall; IQR 31-48 
years); 33 years (IQR 30-41) before 2000; 42 years (IQR 35-46) 
between 2001 and 2003; 40 years (IQR 31-47) between 2004 
and 2006; 41 years (IQR 33-50) between 2007 and 2009; 39 
years (IQR 30-51) between 2010 and 2012, and; 34 years (IQR 
26-44) between 2013 and 2015. The patients with CD4+ cell 
counts lower than 100 cells/mm3 increased until 2012 (Fig. 1). 
However, in the three most recent years (2013-2015), the pro-
portion of patients with lower initial CD4+ cell counts de-
creased. Additionally, the number of patients with CD4+ cell 
counts of more than 350 cells/mm3 at the time of diagnosis 
has increased (Fig. 1). However, patients with CD4+ cell 
counts lower than 100 cells/mm3 at diagnosis were still a sub-
stantial portion (10-33%) of the cohort study population (Fig. 
1). CD4+ cell counts lower than 200 cells/mm3 at diagnosis in-
creased over time (31-51%, maximum at 2010-2012 period). 
CD4+ cell counts lower than 350 cells/mm3 at diagnosis in-
creased over time as well (55-75%, maximum at 2010-2012 
period). 
When the subjects were classified by a CD4+ cell count of 
200 cells/mm3, 467 patients were included in the CD4+ cell 
count ≤200 cells/mm3 group. The median age at diagnosis was 
higher in the group with a CD4+ cell count ≤200 cells/mm3 (41 
years, interquartile range [IQR] 33-49.5) (P = 0.001). With re-
spect to their past medical history, syphilis was observed 
more frequently in patients with a CD4+ cell count >200 cells/
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Figure 1. The trend of CD4+ cell count at the time of diagnosis by 3-year 
intervals. As of 2015, a total of 1,124 HIV-infected patients were included. 
Each period was stratified by grade of CD4+ cell count: ≤100, 101-200, 
201-350, 351-500, and >500 cells/mm3. Values are presented as number 
(percentage).
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mm3 (203 patients, P = 0.029). Tuberculosis was observed 
more frequently in patients with a CD4+ cell count ≤200 cells/
mm3 (109 patients, P <0.0001) (Table 2).  
When the subjects were classified by a CD4+ cell count of 
350 cells/mm3, 778 patients were included in the CD4+ cell 
count ≤350 cells/mm3 group (low CD4+ group) and 346 pa-
tients were included in the CD4+ cell count >350 cells/mm3 
group (high CD4+ group). The median age at diagnosis was 41 
years in the low CD4+ group (IQR 32-49), which was higher 
than that of the high CD4+ group (38.5 years, IQR 31-48) (P = 
0.038). Syphilis was observed in 213 patients in the low CD4+ 
group and in 109 patients in the high CD4+ group, which was 
not statistically significant (P = 0.169). Tuberculosis was ob-
served more frequently in the low CD4+ group (148/778) 
[19%] than in the high CD4+ group (33/346) [9.5%] (P 
<0.0001).
A total of 1,079 HIV-infected patients met the criteria for 
analysis of HIV-RNA titer at the time of diagnosis. Mean and 
median values of HIV-RNA titer were 394,955 copies/mL and 
39,436 copies/mL (IQR, 7,150-151,000 copies/mL), respec-
tively. Until the 2010-2012 period, the proportion of patients 
with HIV-RNA <50,000 copies/mL decreased (Fig. 2). 
2. Trend of CD4+ cell count and HIV-RNA titer at the time 
of initiating HAART 
A total of 376 HIV-infected patients met the criteria for anal-
ysis of CD4+ cell count at time of initiating HAART. Mean and 
median values of CD4+ cell counts were 194 cells/mm3 and 
181 cells/mm3 (IQR, 63-270 cells/mm3), respectively. Median 
value of CD4+ cell count was lowest in 2010-2012 period, and 
those values showed a decrease pattern until 2010-2012 peri-
od (Table 3).
 The overall trend found was that the proportion of patients 
whose CD4+ cell count at initiation of HAART was over 350 
cells/mm3 has decreased (Fig. 3), whereas, the proportion of 
patients with CD4+ cell counts lower than 350 cells/mm3 at 
initiation of HAART has increased. In addition, the proportion 
of patients with CD4+ cell counts lower than 100 cells/mm3 at 
initiation of HAART has increased; in 2010-2012 period, those 
patients account for 43% (Fig. 3). CD4+ cell counts lower than 
200 cells/mm3 at initiation of HAART showed increasing ten-
dency (30-65%, maximum at 2010-2012 period).
A total of 322 HIV-infected patients met the criteria for anal-
Table 2. Factors associated with low CD4+ cell count in patients with HIV 
infection at the time of diagnosis
CD4+ >200
(n=657)
CD4+ ≤200
(n=467)
P-value
Gender 0.550
  Female 48 (7.3) 29 (6.2)
  Male 609 (92.7) 438 (93.8)
Median age at diagnosis 
in years 
39 (30-48) 41 (33-49.5) 0.001
Age at diagnosis 0.002
  ≤29 150 (22.8) 69 (14.8)
30-39 199 (30.3) 130 (27.8)
40-49 166 (25.3) 151 (32.3)
50-59 95 (14.5) 72 (15.4)
≥60 47 (7.2) 45 (9.6)
Estimated transmission 
route
Sexual intercourse 572 (87.1) 404 (86.5) 0.628
- MSMa 287 (43.7) 166 (35.5) 0.007
- Heterosexual 230 (35.0) 202 (43.3) 0.003
- Unknown 55 (8.4) 36 (7.7)
IVDU 0 (0) 5 (1.1) 0.024
Transfusion 9 (1.4) 15 (3.2) 0.045
Injection of coagula-
tion factor 
2 (0.3) 2 (0.4) 1.000
Unknown 74 (11.3) 41 (8.8)
Past medical history
HBV infection 34 (5.2) 19 (4.1) 0.464
HCV infection 6 (0.9) 5 (1.1) 1.000
Syphilis 203 (30.9) 119 (25.5) 0.029
Gonorrhea 43 (6.5) 30 (6.4) 1.000
Non-gonococcal 
urethritis
38 (5.8) 24 (5.1) 0.754
Tuberculosis 72 (11.0) 109 (23.3) <0.0001
Values are presented as median (interquartile range) or number (%).
aMSM included homosexual or bisexual.
HIV, human immunodeficiency virus; MSM, men who have sex with men; IVDU, 
intravenous drug user; HBV, hepatitis B virus; HCV, hepatitis C virus.
Figure 2. The trend of HIV-RNA titer at the time of diagnosis by 3-year 
intervals. As of 2015, a total of 1,079 HIV-infected patients were includ-
ed. Each period was stratified by the level of HIV-RNA titer: ≤50,000, 
500,001-100,000, 100,001-200,000, 200,001-1,000,000, and >1,000,000 
copies/mL. Values are presented as number (percentage).
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ysis of HIV-RNA titers at initiation of HAART. The mean and 
median values of HIV-RNA titers were 493,116 copies/mL and 
83,500 copies/mL (IQR, 15,763-292,500 copies/mL), respec-
tively. The proportion of patients with HIV-RNA <50,000 cop-
ies/mL has steadily decreased, and patients with high RNA ti-
ter at treatment has increased (Fig. 4).
Discussion
Based on Korea HIV/AIDS Cohort Study data, we found 
from our analysis that patients whose CD4+ cell count at the 
time of diagnosis was lower than 350 cells/mm3 accounted for 
Figure 3. The trend of CD4+ cell count at the time of initiating highly ac-
tive antiretroviral therapy by 3-year intervals. As of 2015, 376 HIV patients 
were included. CD4+ cell count, ≤100, 101-200, 201-350, 351-500, and 
>500 cells/mm3, is stratified for each time interval. Values are presented as 
number (percentage).
Figure 4. The trend of HIV-RNA titer at the time of initiating highly active 
antiretroviral therapy by three-year intervals. As of 2015, 322 HIV patients 
were included. Level of HIV-RNA: ≤50,000; 50,001-100,000; 100,001-
200,000; 200,001- 1,000,000; and >1,000,000 copies/mL is stratified for 
each time interval. Values are presented as number (percentage).
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over half of all patients. In particular, the proportion of pa-
tients with CD4+ cell count ≤100 cells/mm3 at the time of di-
agnosis has steadily increased from 2000 to the 2010-2012 
time interval. In other Korea HIV data from the Korea National 
Institute of Health, the proportion of patients with CD4+ T cell 
count <200 cells/mm3 increased from before 1993 to the peri-
od of 2004 to 2006 [15]. Similar to previous reports, our cohort 
data showed gradual increase of patients with CD4+ cell count 
<200 cells/mm3. Presentation of CD4+ cell count lower than 
350 cells/µL at the time of diagnosis has also been found in 
other countries. In northwest Spain data from 2004-2013, 
53.1% of newly infected HIV patients had low CD4+ cell 
counts (CD4+ count <350 cells/mm3) [16]. In the United King-
dom, 49% of newly infected HIV patients in 2011 were diag-
nosed at a low CD4+ cell count, lower than 350 cells/mm3 [17]. 
Shen et al. reported the CD4+ cell count at the time of diagno-
sis in China. From 2009-2010, about 72% of patients had a low 
CD4+ cell count, ≤200 cells/mm3, which was lower than in our 
report [18].
Our study showed that many patients initiated HAART at a 
low CD4+ cell count. The proportion of patients with a low 
CD4+ cell count at time of HAART initiation gradually in-
creased until recently. We think that this result is influenced 
by an increase in patients with low CD4+ cell count at the time 
of diagnosis. More patients with CD4+ cell count ≤100 cells/
µL at time of diagnosis have been observed, and this tendency 
has increased over time. 
In contrast to our national trends, recent reports from Asia 
showed a tendency towards increased CD4+ cell count at ini-
tiation of treatment. The TAHOD-TASER Cohort Study report-
ed trends of CD4+ cell count at the initiation of HAART over 
time. Before 2010, median CD4+ cell count at the start of treat-
ment was lower than 200 cells/mm3. Since 2011, median 
CD4+ cell count has been increasing substantially. The medi-
an CD4+ cell count in 2011 and after 2011 was 249 cells/mm3 
and 302 cells/mm3, respectively. In addition, the proportion of 
patients with CD4+ cell count <200 cells/mm3 at initiation of 
HAART markedly decreased over time, from 82.4% in 2007 to 
36.3% after 2011 [2]. This CD4+ cell count trend was similar to 
the findings from a study performed in Shanghai, China. The 
median CD4+ cell count had increased from 65 cells/mm3 in 
2006 to 203 cells/mm3 in 2011. The proportion of patients with 
CD4+ cell count <200 cells/mm3 decreased from 88.5% in 
2006 to 49.6% in 2011 [19]. In Rwanda, an upswing in the me-
dian CD4+ cell count at HAART initiation was observed. 
While the median CD4+ cell count was 183 cells/mm3 in 2007, 
the median CD4+ cell count was 293 cells/mm3 in 2011-2012. 
The proportion of patients with advanced HIV disease (CD4+ 
cell count <200 cells/mm3 or WHO stage IV) had decreased 
from 66.2% to 29.4% [20]. In these three studies, the propor-
tion of patients with CD4+ cell count <200 cells/mm3 at 
HAART initiation, after 2010, was similar to our findings. How-
ever, the findings showed improvement in CD4+ cell counts at 
HAART initiation, which was in contrast to what we observed 
in our cohort data. Research from industrialized countries 
show a stable median CD4+ cell count over 300 cells/mm3 at 
HAART initiation for a period of about twenty years [21, 22]. 
In this study, consistent low median CD4+ cell counts have 
been observed, which were lower than those observed in oth-
er developed countries. 
Upon comparing the factors based on the CD4+ cell count 
at diagnosis (cutoff point: 200 cells/mm3 or 350 cells/mm3), 
the median age at diagnosis was higher in patients with a low 
CD4+ cell count than in patients with a high CD4+ cell count. 
In addition, between 2001 and 2012, the median age at diag-
nosis for each period was high. Among the associated risk fac-
tors, a history of tuberculosis was observed more frequently in 
patients with a low CD4+ cell count. This finding may be asso-
ciated with the risk of opportunistic tuberculous infection. 
Moreover, sexual contact among males and a history of syphi-
lis were more frequently recorded in patients with a high 
CD4+ cell count. This finding suggests that the opportunity of 
diagnostic test would have influenced the rate of low CD4+ 
cell count at diagnosis.
Our study has limitations. The size of the study population, 
when divided into each three-year interval time period, was 
small. However, we believe our cohort data provides an un-
derstanding of early-stage immune status of Korean HIV pa-
tients, as well as CD4+ status at initial treatment. 
In summary, the Korea HIV/AIDS Cohort Study population 
comprised patients who had CD4+ cell count and HIV-RNA ti-
ter values at the time of diagnosis and initiation of HAART. 
Our findings, based on analysis of cohort study data, suggest 
that early detection of HIV patients and earlier initiation of 
HAART, to treat and prevent the spread of HIV infection, is 
needed.
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